| Literature DB >> 30234074 |
Linus D Kloker1, Can Yurttas2, Ulrich M Lauer1,3.
Abstract
Oncolytic virotherapy constitutes an upcoming alternative treatment option for a broad spectrum of cancer entities. However, despite great research efforts, there is still only a single US Food and Drug Administration/European Medicines Agency-approved oncolytic virus available for clinical use. One reason for that is the gap between promising preclinical data and limited clinical success. Since oncolytic viruses are biological agents, they might require more realistic in vitro tumor models than common monolayer tumor cell cultures to provide meaningful predictive preclinical evaluation results. For more realistic invitro tumor models, three-dimensional tumor cell-culture systems can be employed in preclinical virotherapy research. This review provides an overview of spheroid and hydrogel tumor cell cultures, organotypic tumor-tissue slices, organotypic raft cultures, and tumor organoids utilized in the context of oncolytic virotherapy. Furthermore, we also discuss advantages, disadvantages, techniques, and difficulties of these three-dimensional tumor cell-culture systems when applied specifically in virotherapy research.Entities:
Keywords: oncolytic virotherapy; oncolytic viruses; preclinical testing; three-dimensional cell culture; tumor modeling
Year: 2018 PMID: 30234074 PMCID: PMC6130269 DOI: 10.2147/OV.S165479
Source DB: PubMed Journal: Oncolytic Virother ISSN: 2253-1572
Figure 1Spheroid and hydrogel culture.
Notes: (A) Depiction of a stained histological section through a large spheroid (up to 1 mm in diameter) makes different metabolic zones visible. Nutrition, oxygen, and drug concentrations are higher at the rim of the spheroid, whereas low pH and accumulation of CO2 and metabolic end products lead to necrosis in the core of the spheroid.
Adapted from Verjans ET, Doijen J, Luyten W, Landuyt B, Schoofs L. Three-dimensional cell culture models for anticancer drug screening: worth the effort? J Cell Physiol. 2018;233(4):2993–3003. © 2017 Wiley Periodicals, Inc.93 Adapted from Lin RZ, Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J. 2008;3(9–10):1172–1184. Copyright 2008 Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission.94 (B) Depiction of a single well with a hydrogel culture. Single cells have been taken up in fluid hydrogel. When it solidifies, cells are embedded in a three-dimensional matrix that allows medium supply.
Virotherapy studies employing tumor cell spheroids
| 3-D culture system | Tumor entity | OV | Notes | Reference |
|---|---|---|---|---|
| Spheroids | Bladder cancer | Adenovirus | Targeting cancer-initiating cells with an OV | |
| Colon carcinoma | Adenovirus | Mechanism of viral spread and penetration in epithelial tissue | ||
| Echovirus | Oncolytic activity in 2-D and 3-D cultures | |||
| Echovirus 5 | Using an altered infectious nucleic acid to initiate and improve viral replication | |||
| Newcastle disease virus | Development of more potent OVs by bioselection | |||
| Glioblastoma | HSV1 | Replication and oncolytic activity in animal models and spheroids | ||
| Reovirus | Analysis of oncolytic activity in 2-D and 3-D glioblastoma stem-like cells | |||
| Reovirus | Different entry pathways in 2-D and spheroid cultures | |||
| VSV | Development and testing of a semireplication-competent VSV to improve safety | |||
| Glioblastoma, neuroblastoma | HSV1 | Degradation of ECM to enhance oncolytic activity | ||
| Glioma | Adenovirus | Analysis of oncolytic activity, combinatorial virotherapy with temozolomide and suicide gene | ||
| Adenovirus | Evaluation of oncolytic activity with PET and WST1 assay | |||
| Adenovirus | Combination of radiation and OV | |||
| Glioma, breast cancer | Adenovirus | Decorin transgene to improve viral spread by degrading the ECM | ||
| Hepatocellular carcinoma | Adenovirus | Targeting Wnt signaling in hepatocellular carcinoma stem-like cells | ||
| Lung cancer | Adenovirus | Targeting lung cancer stem-like cells | ||
| Melanoma, breast cancer | HSV2 | Oncolytic mechanism and role of the calpain system in cancer stem-like cells | ||
| NSCLC | Newcastle disease virus | Oncolytic mechanism of Newcastle disease virus, influence of autophagy | ||
| Ovarian cancer | Adenovirus | Measurement of oncolysis in spheroids via luciferase expression | ||
| Adenovirus | Different efficacy in different patient samples | |||
| Adenovirus | Virus replication and measurement in 3-D cultures | |||
| Adenovirus | Development and preclinical testing of a novel OV | |||
| Echovirus 1 | Preclinical testing of oncolytic potential | |||
| Myxoma virus | Different oncolytic activity in adherent and nonadherent cells | |||
| Myxoma virus, vaccinia virus, Maraba virus | Different oncolytic activity in 2D vs 3-D cultures | |||
| Vaccinia virus | Targeting cancer-initiating cells with chemokine-receptor antagonist expressing OV | |||
| Pancreatic cancer | Adenovirus | Reduction of gemcitabine resistance by degrading ECM with OV | ||
| Panel of tumor cell lines | Adenovirus | Degradation of ECM to increase viral distribution and penetration | ||
| Panel of tumor cell lines | Coronavirus | Targeting coronaviruses to EGF receptor with a bispecific antibody | ||
| Pediatric glioma | HSV1 | Oncolytic mechanism of action, OV as an anti-invasive treatment | ||
| Spheroids, chicken chorioallantoic membrane models | Pancreatic cancer | Adenovirus | OV delivery using mesenchymal stromal cells | |
| Spheroids placed on brain slices | Glioma | HSV1 | ECM degradation by chondroitinase ABC enhances antitumor efficacy | |
| Vaccinia virus | Influence of microglia and astrocytes on oncolytic activity | |||
| Spheroid coculture in PEG diacrylate hydrogels | Glioblastoma | Adenovirus | Oncolytic potential in 3-D cocultures | |
| Neurospheres | Glioblastoma | Adenovirus | Targeting brain-tumor stem-like cells | |
| Adenovirus | Targeting brain-tumor stem-like cells, role of autophagy | |||
| HSV1 | Sensitizing of glioblastomas to temozolomide by OV expressing chondroitinase M | |||
| Measles vaccine virus | Preclinical testing of OV in tumor stem-like cells | |||
| Parvovirus H1 | Oncolytic activity in glioblastoma stem-like cells |
Abbreviations: 2-D, two-dimensional; 3-D, three-dimensional; ECM, extracellular matrix; HSV, herpes simplex virus; NSCLC, non-small-cell lung cancer; OV, oncolytic virus; PEG, polyethylene glycol; PET, positron-emission tomography; VSV, vesicular stomatitis virus.
Summary of advantages and disadvantages of the five cell-culture systems
| Cell-culture system | Advantages | Disadvantages |
|---|---|---|
| Spheroids | Different metabolic zones and physical gradients | Only one cell type contained and hence provides an inadequate representation of the tumor microenvironment |
| Hydrogel cultures | Cell–virus ECM interactions can be studied; coculture with fibroblasts or even endothelial cells is easy | Hydrogel composition may influence cells and differs from real tumor ECM; lower cell density than normal tissue |
| Organotypic tissue cultures | Closest to in vivo tumor histology; contain stromal and immune cells, as well as tumor endothelium | Differences between the specimens; only culturable for a few days |
| Organotypic raft cultures | Resemble epithelial architecture and differentiation | Only suitable for epithelial tissues |
| Organoids | Contain stem cells and differentiated cells; relatively easy to maintain; can be shared and expanded; maintain genetic tumor patterns | Expensive culture materials; niche and growth factors might change tumor behavior |
Abbreviation: ECM, ext racellular matrix.
Virotherapy studies using hydrogel culture models
| 3-D culture system | Tumor entity | OV | Notes | Reference |
|---|---|---|---|---|
| Collagen-gel coculture model | Breast cancer | Measles vaccine virus | Targeting tumor stroma with OV | |
| Matrigel cultures | Epithelial ovarian cancer | Adenovirus | Development of OVs using directed evolution in 2-D vs 3-D cultures | |
| Prostate adenocarcinoma, breast adenocarcinoma, embryonic teratocarcinoma | HSV1 | Oncolytic activity in 2-D vs 3-D cultures; impact of ECM on resistance | ||
| Prostate cancer | Adenovirus | Targeting tumor and tumor endothelium | ||
| Uveal melanoma | HSV1 | Identification of resistant tumor cell populations; impact of ECM | ||
| PEG–fibrin hydrogel | Lung adenocarcinoma | Adenovirus | Oncolytic activity in 3-D cultures, role of stromal components and microenvironment |
Abbreviations: 2-D, two-dimensional; 3-D, three-dimensional; ECM, extracellular matrix; HSV, herpes simplex virus; OV, oncolytic virus.
Figure 2Organotypic tissue slices and organoids.
Notes: (A) Preparation of an organotypic tissue slice. After cutting, slices can be cultured in cell-culture media for several days. Special inserts in culture dishes ensure that the slices are close to the surface of the culture medium for a sufficient oxygen supply. (B) Organoid culture, stem cells provided with stem cell, and niche factors form organoids in a three-dimensional matrix (in general hydrogel). A section through a spherical organoid (up to 500 µm in diameter) is enlarged so that single cells become visible. Stem-like cells are shown in red and differentiated cells in yellow. Cells in organoids form a flat structured surface outward. Internally, they build a lumen in which dead cells accumulate after some time.
Virotherapy studies employing organotypic tissue cultures
| 3-D culture system | Tumor entity | OV | Notes | Reference |
|---|---|---|---|---|
| Organotypic slices | Breast cancer | Adenovirus | Tumor specificity using mRNA translational control | |
| Replication and infectivity in 3-D cultures | ||||
| Comparison of efficacy of different adenoviruses | ||||
| Tissue-specific promoters to provide tumor specificity | ||||
| Colon carcinoma | Adenovirus | Precision-cut tumor-tissue slices for preclinical evaluation | ||
| Glioma | Adenovirus | Developing and testing of a TRAIL-armed OV | ||
| HSV1 | Impact of macrophage and microglia depletion on intratumoral virus titers | |||
| Vesicular stomatitis virus | Oncolytic activity and toxicity of vesicular stomatitis virus | |||
| Liver slices | Adenovirus | Hepatotoxicity of oncolytic adenovirus | ||
| Melanoma | Newcastle disease virus | Influence of ECM on virus spread and oncolysis | ||
| Primary and secondary liver tumors | Measles vaccine virus | Precision-cut liver tumor slices for preclinical evaluation of oncolytic measles vaccine virus | ||
| Prostate cancer, brain tumors | HSV1 | Protocol for testing HSV1 in organotypic cultures | ||
| Tissue explants | Bladder cancer | Vaccinia virus | Preclinical testing of selectivity and safety of vaccinia virus | |
| Colorectal cancer, cervical cancer | Vaccinia virus | Clinical trial for intravenous application of a vaccinia virus targeting the Ras pathway | ||
| Prostate cancer | HSV1 | Analysis of oncolytic activity and mechanism | ||
| Combining vinblastine and OV to target tumor and neovasculature |
Abbreviations: 3-D, three-dimensional; ECM, extracellular matrix; HSV, herpes simplex virus; OV, oncolytic virus.
Virotherapy studies using organotypic raft cultures, the CAM model, or organoid culture
| 3-D culture system | Tumor entity | Oncolytic virus | Notes | Reference |
|---|---|---|---|---|
| CAM | Melanoma, colorectal carcinoma, glioblastoma | Adenovirus | CAM tumor assay for preclinical testing of adenoviruses | |
| Organotypic raft cultures | Cervical cancer | Adenovirus | Safety and efficacy of oncolytic adenoviruses | |
| Cervical cancer | Adenovirus | Organotypic keratinocyte culture for preclinical testing of oncolytic adenoviruses | ||
| Head-and-neck squamous-cell carcinomas | Adenovirus | Targeting adenoviruses to surface antigens with antibodies | ||
| Melanoma | Adenovirus | Different cell selectivity in 2-D vs 3-D cultures | ||
| Organoids | Glioblastoma | Zika virus | Oncolytic activity and specificity to glioblastoma stem-like cells |
Abbreviations: 2-D, two-dimensional; 3-D, three-dimensional; CAM, chicken chorioallantoic membrane.
Figure 3Individual patient virogram employing patient-derived tumor organoids.
Abbreviation: OV, oncolytic virus.